Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis

Journal of Medicinal Chemistry

Volumn 61, Issue 19, 2018, Pages 8563-8593

  Chikhale, Rupesh V ^a,b   Barmade, Mahesh A ^a   Murumkar, Prashant R ^a   Yadav, Mange Ram ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOGALACTAN; BENZAMIDE DERIVATIVE; DECAPRENYLPHOSPHORYL BETA DEXTRO RIBOSE 2' EPIMERASE 1; DECAPRENYLPHOSPHORYL BETA DEXTRO RIBOSE 2' EPIMERASE 1 INHIBITOR; EPIMERASE; LIGAND; LIPOARABINOMANNAN; NITRO DERIVATIVE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE; QUINOXALINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; BACTERIAL PROTEIN; DPRE1 PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CHEMICAL MODIFICATION; COVALENT BOND; CRYSTAL STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME MECHANISM; HIGH THROUGHPUT SCREENING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOPHORE; REVIEW; TUBERCULOSIS; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; MICROBIOLOGY;

ALCOHOL OXIDOREDUCTASES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DEVELOPMENT; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 85048038942     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.8b00281     Document Type: Review

References (162)

1. Lamichhane et al. Trends Mol. Med. (https://www.sciencedirect.com/journal/trends-in-molecular-medicine) 2011, 17, 25-33
2. Makarov et al. EMBO Mol. Med. 2014, 6, 372-383
3. Landge et al. Bioorg. Med. Chem. (https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry) 2015, 23, 7694-7710
4. Neres et al. ACS Chem. Biol. 2015, 10, 705-714
5. Shirude et al. J. Med. Chem. 2014, 57, 5728-5737
6. Panda et al. J. Med. Chem. 2014, 57, 4761-4771
7. Naik et al. J. Med. Chem. 2014, 57, 5419-5434
8. Hayman, J. Mycobacterium ulcerans: An infection from Jurassic time?. Lancet 1984, 324, 1015-1016, 10.1016/S0140-6736(84)91110-3
9. Gutierrez, M. C.; Brisse, S.; Brosch, R.; Fabre, M.; Omaïs, B.; Marmiesse, M.; Supply, P.; Vincent, V. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog. 2005, 1, e5, 10.1371/journal.ppat.0010005
10. Kapur, V.; Whittam, T. S.; Musser, J. M. Is Mycobacterium tuberculosis 15,000 years old?. J. Infect. Dis. 1994, 170, 1348-1349, 10.1093/infdis/170.5.1348
11. Cave, A.; Demonstrator, A. The evidence for the incidence of tuberculosis in ancient Egypt. Br. J. Tuberc. 1939, 33, 142-152, 10.1016/S0366-0850(39)80016-3
12. Sreevatsan, S.; Pan, X.; Stockbauer, K. E.; Connell, N. D.; Kreiswirth, B. N.; Whittam, T. S.; Musser, J. M. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 9869-9874, 10.1073/pnas.94.18.9869
13. Clarke, S. M.; Mulcahy, F. M.; Tjia, J.; Reynolds, H. E.; Gibbons, S. E.; Barry, M. G.; Back, D. J. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 2001, 51, 213-217, 10.1046/j.1365-2125.2001.00342.x
14. Grigg, E. The arcana of tuberculosis with a brief epidemiologic history of the disease in the USA. Am. Rev. Tuberc. 1958, 78, 151-172
15. Koch, R. Die aetiologie der tuberkulose. Klin. Wochenschr. 1932, 11, 490-492, 10.1007/BF01765224
16. Koch, R. Fortsetzung der Mittheilungen über ein Heilmittel gegen Tuberculose. Dtsch. Med. Wochenschr. 1891, 17, 101-102, 10.1055/s-0029-1206198
17. Daniel, T. Robert Koch and the pathogenesis of tuberculosis [Founders of Our Knowledge]. Int. J. Tuberc. Lung Dis. 2005, 9, 1181-1182
18. Ryan, F. Tuberculosis: The Greatest Story Never Told: The Human Story of the Search for the Cure for Tuberculosis and the New Global Threat; FPR-Books Ltd., 1992.
19. Global Tuberculosis Report 2015; World Health Organization: Geneva, 2015.
20. Dannenberg, A. M., Jr. Lurie's tubercle-count method to test TB vaccine efficacy in rabbits. Front. Biosci., Landmark Ed. 1998, 3, 27-33, 10.2741/A261
21. Weiss, G.; Schaible, U. E. Macrophage defense mechanisms against intracellular bacteria. Immunol. Rev. 2015, 264, 182-203, 10.1111/imr.12266
22. Deretic, V.; Fratti, R. Mycobacterium tuberculosis phagosome. Mol. Microbiol. 1999, 31, 1603-1609, 10.1046/j.1365-2958.1999.01279.x
23. Mukadi, Y. D.; Maher, D.; Harries, A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001, 15, 143-152, 10.1097/00002030-200101260-00002
24. Dye, C.; Scheele, S.; Dolin, P.; Pathania, V.; Raviglione, M. C. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. JAMA 1999, 282, 677-686, 10.1001/jama.282.7.677
25. Dheda, K.; Barry, C. E.; Maartens, G. Lancet 2016, 387, 1211-1226, 10.1016/S0140-6736(15)00151-8
26. Zumla, A.; Chakaya, J.; Centis, R.; D'Ambrosio, L.; Mwaba, P.; Bates, M.; Kapata, N.; Nyirenda, T.; Chanda, D.; Mfinanga, S.; Hoelscher, M.; Maeurer, M.; Migliori, G. B. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir. Med. 2015, 3, 220-234, 10.1016/S2213-2600(15)00063-6
27. Walter, N. D.; Strong, M.; Belknap, R.; Ordway, D. J.; Daley, C. L.; Chan, E. D. Translating basic science insight into public health action for multidrug-and extensively drug-resistant tuberculosis. Respirology 2012, 17, 772-791, 10.1111/j.1440-1843.2012.02176.x
28. Mase, S.; Chorba, T.; Lobue, P.; Castro, K. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Morbid. Mortal. Wkly. Rep. 2013, 62, 1-12
29. Parida, S.; Axelsson-Robertson, R.; Rao, M.; Singh, N.; Master, I.; Lutckii, A.; Keshavjee, S.; Andersson, J.; Zumla, A.; Maeurer, M. Totally drug-resistant tuberculosis and adjunct therapies. J. Intern. Med. 2015, 277, 388-405, 10.1111/joim.12264
30. Camacho, L. R.; Ensergueix, D.; Perez, E.; Gicquel, B.; Guilhot, C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 1999, 34, 257-267, 10.1046/j.1365-2958.1999.01593.x
31. Rubin, E. J.; Akerley, B. J.; Novik, V. N.; Lampe, D. J.; Husson, R. N.; Mekalanos, J. J. In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 1645-1650, 10.1073/pnas.96.4.1645
32. Sassetti, C. M.; Boyd, D. H.; Rubin, E. J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 2003, 48, 77-84, 10.1046/j.1365-2958.2003.03425.x
33. Rengarajan, J.; Bloom, B. R.; Rubin, E. J. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 8327-8332, 10.1073/pnas.0503272102
34. Stanley, S. A.; Grant, S. S.; Kawate, T.; Iwase, N.; Shimizu, M.; Wivagg, C.; Silvis, M.; Kazyanskaya, E.; Aquadro, J.; Golas, A.; Fitzgerald, M.; Dai, H.; Zhang, L.; Hung, D. T. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 2012, 7, 1377-1384, 10.1021/cb300151m
35. Mokrousov, I.; Chernyaeva, E.; Vyazovaya, A.; Sinkov, V.; Zhuravlev, V.; Narvskaya, O. Next-generation sequencing of Mycobacterium tuberculosis. Emerging Infect. Dis. 2016, 22, 1127, 10.3201/eid2206.152051
36. Emig, D.; Ivliev, A.; Pustovalova, O.; Lancashire, L.; Bureeva, S.; Nikolsky, Y.; Bessarabova, M. Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013, 8, e60618, 10.1371/journal.pone.0060618
37. Berger, S. I.; Iyengar, R. Network analyses in systems pharmacology. Bioinformatics 2009, 25, 2466-2472, 10.1093/bioinformatics/btp465
38. Lavecchia, A. Machine-learning approaches in drug discovery: Methods and applications. Drug Discovery Today 2015, 20, 318-331, 10.1016/j.drudis.2014.10.012
39. Lee, G. Y.; Kenny, P. A.; Lee, E. H.; Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4, 359-365, 10.1038/nmeth1015
40. Kaufmann, S. H.; Parida, S. K. Changing funding patterns in tuberculosis. Nat. Med. 2007, 13, 299-303, 10.1038/nm0307-299
41. Jain, S. K.; Hernandez-Abanto, S. M.; Cheng, Q.-J.; Singh, P.; Ly, L. H.; Klinkenberg, L. G.; Morrison, N. E.; Converse, P. J.; Nuermberger, E.; Grosset, J.; McMurray, D. N.; Karakousis, P. C.; Lamichhane, G.; Bishai, W. R. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J. Infect. Dis. 2007, 195, 1634-1642, 10.1086/517526
42. Boshoff, H. I.; Myers, T. G.; Copp, B. R.; McNeil, M. R.; Wilson, M. A.; Barry, C. E. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism novel insights into drug mechanisms of action. J. Biol. Chem. 2004, 279, 40174-40184, 10.1074/jbc.M406796200
43. Ioerger, T. R.; Sacchettini, J. C. Structural genomics approach to drug discovery for Mycobacterium tuberculosis. Curr. Opin. Microbiol. 2009, 12, 318-325, 10.1016/j.mib.2009.04.006
44. Lamichhane, G. Novel targets in M. tuberculosis: Search for new drugs. Trends Mol. Med. 2011, 17, 25-33, 10.1016/j.molmed.2010.10.004
45. Kalscheuer, R.; Syson, K.; Veeraraghavan, U.; Weinrick, B.; Biermann, K. E.; Liu, Z.; Sacchettini, J. C.; Besra, G.; Bornemann, S.; Jacobs, W. R., Jr Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an α-glucan pathway. Nat. Chem. Biol. 2010, 6, 376, 10.1038/nchembio.340
46. Veleti, S. K.; Lindenberger, J. J.; Ronning, D. R.; Sucheck, S. J. Synthesis of a C-phosphonate mimic of maltose-1-phosphate and inhibition studies on Mycobacterium tuberculosis GlgE. Bioorg. Med. Chem. 2014, 22, 1404-1411, 10.1016/j.bmc.2013.12.058
47. Glickman, M. S.; Cox, J. S.; Jacobs, W. R., Jr A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 2000, 5, 717-727, 10.1016/S1097-2765(00)80250-6
48. Stanley, S. A.; Kawate, T.; Iwase, N.; Shimizu, M.; Clatworthy, A. E.; Kazyanskaya, E.; Sacchettini, J. C.; Ioerger, T. R.; Siddiqi, N. A.; Minami, S.; Aquadro, J. A.; Grant, S. S.; Rubin, E. J.; Hung, D. T. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 11565-11570, 10.1073/pnas.1302114110
49. Ouellet, H.; Johnston, J. B.; de Montellano, P. R. O. Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis. Trends Microbiol. 2011, 19, 530-539, 10.1016/j.tim.2011.07.009
50. Makarov, V.; Manina, G.; Mikusova, K.; Möllmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M. R.; Buroni, S.; Lucarelli, A. P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C.; Fullam, E.; Schneider, P.; McKinney, J. D.; Brodin, P.; Christophe, T.; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R. K.; Balasubramanian, V.; Balganesh, T.; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S. T. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324, 801-804, 10.1126/science.1171583
51. Christophe, T.; Jackson, M.; Jeon, H. K.; Fenistein, D.; Contreras-Dominguez, M.; Kim, J.; Genovesio, A.; Carralot, J.-P.; Ewann, F.; Kim, E. H.; Lee, S. Y.; Kang, S.; Seo, M. J.; Park, E. J.; Skovierová, H.; Pham, H.; Riccardi, G.; Nam, J. Y.; Marsollier, L.; Kempf, M.; Joly-Guillou, M. L.; Oh, T.; Shin, W. K.; No, Z.; Nehrbass, U.; Brosch, R.; Cole, S. T.; Brodin, P. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 2009, 5, e1000645, 10.1371/journal.ppat.1000645
52. Sareen, D.; Newton, G. L.; Fahey, R. C.; Buchmeier, N. A. Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. J. Bacteriol. 2003, 185, 6736-6740, 10.1128/JB.185.22.6736-6740.2003
53. Gutierrez-Lugo, M.-T.; Baker, H.; Shiloach, J.; Boshoff, H.; Bewley, C. A. Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. J. Biomol. Screening 2009, 14, 643-652, 10.1177/1087057109335743
54. Parish, T. Starvation survival response of Mycobacterium tuberculosis. J. Bacteriol. 2003, 185, 6702-6706, 10.1128/JB.185.22.6702-6706.2003
55. Cho, Y.; Ioerger, T. R.; Sacchettini, J. C. Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J. Med. Chem. 2008, 51, 5984-5992, 10.1021/jm800328v
56. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H. W.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307, 223-227, 10.1126/science.1106753
57. Koul, A.; Vranckx, L.; Dendouga, N.; Balemans, W.; Van den Wyngaert, I.; Vergauwen, K.; Göhlmann, H. W.; Willebrords, R.; Poncelet, A.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 2008, 283, 25273-25280, 10.1074/jbc.M803899200
58. Teo, J. W.; Thayalan, P.; Beer, D.; Yap, A. S.; Nanjundappa, M.; Ngew, X.; Duraiswamy, J.; Liung, S.; Dartois, V.; Schreiber, M.; Hasan, S.; Cynamon, M.; Ryder, S. N.; Yang, X.; Weidmann, B.; Bracken, K.; Dick, T.; Mukherjee, K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother. 2006, 50, 3665-3673, 10.1128/AAC.00555-06
59. Hackbarth, C. J.; Chen, D. Z.; Lewis, J. G.; Clark, K.; Mangold, J. B.; Cramer, J. A.; Margolis, P. S.; Wang, W.; Koehn, J.; Wu, C.; Lopez, S.; Withers, G.; Gu, H.; Dunn, E.; Kulathila, R.; Pan, S. H.; Porter, W. L.; Jacobs, J.; Trias, J.; Patel, D. V.; Weidmann, B.; White, R. J.; Yuan, Z. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 2002, 46, 2752-2764, 10.1128/AAC.46.9.2752-2764.2002
60. Lamichhane, G.; Zignol, M.; Blades, N. J.; Geiman, D. E.; Dougherty, A.; Grosset, J.; Broman, K. W.; Bishai, W. R. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 7213-7218, 10.1073/pnas.1231432100
61. Olaleye, O.; Raghunand, T. R.; Bhat, S.; He, J.; Tyagi, S.; Lamichhane, G.; Gu, P.; Zhou, J.; Zhang, Y.; Grosset, J.; Bishai, W. R.; Liu, J. O. Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets. Chem. Biol. 2010, 17, 86-97, 10.1016/j.chembiol.2009.12.014
62. Stallings, C. L.; Stephanou, N. C.; Chu, L.; Hochschild, A.; Nickels, B. E.; Glickman, M. S. CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 2009, 138, 146-159, 10.1016/j.cell.2009.04.041
63. Primm, T. P.; Andersen, S. J.; Mizrahi, V.; Avarbock, D.; Rubin, H.; Barry, C. E. The stringent response of Mycobacterium tuberculosis is required for long-term survival. J. Bacteriol. 2000, 182, 4889-4898, 10.1128/JB.182.17.4889-4898.2000
64. Park, H. D.; Guinn, K. M.; Harrell, M. I.; Liao, R.; Voskuil, M. I.; Tompa, M.; Schoolnik, G. K.; Sherman, D. R. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 2003, 48, 833-843, 10.1046/j.1365-2958.2003.03474.x
65. Voskuil, M. I.; Schnappinger, D.; Visconti, K. C.; Harrell, M. I.; Dolganov, G. M.; Sherman, D. R.; Schoolnik, G. K. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 2003, 198, 705-713, 10.1084/jem.20030205
66. Wisedchaisri, G.; Wu, M.; Rice, A. E.; Roberts, D. M.; Sherman, D. R.; Hol, W. G. Structures of Mycobacterium tuberculosis DosR and DosR-DNA complex involved in gene activation during adaptation to hypoxic latency. J. Mol. Biol. 2005, 354, 630-641, 10.1016/j.jmb.2005.09.048
67. Schnappinger, D.; Ehrt, S.; Voskuil, M. I.; Liu, Y.; Mangan, J. A.; Monahan, I. M.; Dolganov, G.; Efron, B.; Butcher, P. D.; Nathan, C.; Schoolnik, G. K. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J. Exp. Med. 2003, 198, 693-704, 10.1084/jem.20030846
68. McKinney, J. D.; Zu Bentrup, K. H.; MunÌoz-Eliás, E. J.; Miczak, A.; Chen, B.; Chan, W.-T.; Swenson, D.; Sacchettini, J. C.; Jacobs, W. R., Jr; Russell, D. G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406, 735-738, 10.1038/35021074
69. MunÌoz-Eliás, E. J.; McKinney, J. D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 2005, 11, 638-644, 10.1038/nm1252
70. Lavollay, M.; Arthur, M.; Fourgeaud, M.; Dubost, L.; Marie, A.; Veziris, N.; Blanot, D.; Gutmann, L.; Mainardi, J. L. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, D-transpeptidation. J. Bacteriol. 2008, 190, 4360-4366, 10.1128/JB.00239-08
71. Gupta, R.; Lavollay, M.; Mainardi, J.-L.; Arthur, M.; Bishai, W. R.; Lamichhane, G. The Mycobacterium tuberculosis protein Ldt Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 2010, 16, 466-469, 10.1038/nm.2120
72. Darwin, K. H. Prokaryotic ubiquitin-like protein (Pup), proteasomes and pathogenesis. Nat. Rev. Microbiol. 2009, 7, 485-491, 10.1038/nrmicro2148
73. Darwin, K. H.; Ehrt, S.; Gutierrez-Ramos, J.-C.; Weich, N.; Nathan, C. F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 2003, 302, 1963-1966, 10.1126/science.1091176
74. Valway, S. E.; Sanchez, M. P. C.; Shinnick, T. F.; Orme, I.; Agerton, T.; Hoy, D.; Jones, J. S.; Westmoreland, H.; Onorato, I. M. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 1998, 338, 633-639, 10.1056/NEJM199803053381001
75. Lamichhane, G.; Raghunand, T. R.; Morrison, N. E.; Woolwine, S. C.; Tyagi, S.; Kandavelou, K.; Bishai, W. R. Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues. J. Infect. Dis. 2006, 194, 1233-1240, 10.1086/508288
76. Hu, G.; Lin, G.; Wang, M.; Dick, L.; Xu, R. M.; Nathan, C.; Li, H. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol. 2006, 59, 1417-1428, 10.1111/j.1365-2958.2005.05036.x
77. Groll, M.; Brandstetter, H.; Bartunik, H.; Bourenkow, G.; Huber, R. Investigations on the maturation and regulation of archaebacterial proteasomes. J. Mol. Biol. 2003, 327, 75-83, 10.1016/S0022-2836(03)00080-9
78. Lin, G.; Li, D.; de Carvalho, L. P. S.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J. D.; Li, H.; Nathan, C. Inhibitors selective for mycobacterial versus human proteasomes. Nature 2009, 461, 621-626, 10.1038/nature08357
79. Gandotra, S.; Schnappinger, D.; Monteleone, M.; Hillen, W.; Ehrt, S. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 2007, 13, 1515-1520, 10.1038/nm1683
80. Gandotra, S.; Lebron, M. B.; Ehrt, S. The Mycobacterium tuberculosis proteasome active site threonine is essential for persistence yet dispensable for replication and resistance to nitric oxide. PLoS Pathog. 2010, 6, e1001040, 10.1371/journal.ppat.1001040
81. Khan, S.; Nagarajan, S. N.; Parikh, A.; Samantaray, S.; Singh, A.; Kumar, D.; Roy, R. P.; Bhatt, A.; Nandicoori, V. K. Phosphorylation of enoyl-acyl carrier protein reductase InhA impacts mycobacterial growth and survival. J. Biol. Chem. 2010, 285, 37860-37871, 10.1074/jbc.M110.143131
82. Choi, K.-H.; Kremer, L.; Besra, G. S.; Rock, C. O. Identification and substrate specificity of β-ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J. Biol. Chem. 2000, 275, 28201-28207, 10.1074/jbc.M003241200
83. Kolly, G. S.; Mukherjee, R.; Kilacsková, E.; Abriata, L. A.; Raccaud, M.; Blaško, J.; Sala, C.; Dal Peraro, M.; Mikušová, K.; Cole, S. T. GtrA protein Rv3789 is required for arabinosylation of arabinogalactan in Mycobacterium tuberculosis. J. Bacteriol. 2015, 197, 3686-3697, 10.1128/JB.00628-15
84. Bruning, J. B.; Murillo, A. C.; Chacon, O.; Barletta, R. G.; Sacchettini, J. C. Structure of the Mycobacterium tuberculosis D-alanine: D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob. Agents Chemother. 2011, 55, 291-301, 10.1128/AAC.00558-10
85. Garner, A. L.; Weiss, L. A.; Manzano, A. R.; Galburt, E. A.; Stallings, C. L. CarD integrates three functional modules to promote efficient transcription, antibiotic tolerance, and pathogenesis in mycobacteria. Mol. Microbiol. 2014, 93, 682-697, 10.1111/mmi.12681
86. Rammohan, J.; Ruiz Manzano, A.; Garner, A. L.; Prusa, J.; Stallings, C. L.; Galburt, E. A. Cooperative stabilization of Mycobacterium tuberculosis rrnA P3 promoter open complexes by RbpA and CarD. Nucleic Acids Res. 2016, 44, 7304-7313, 10.1093/nar/gkw577
87. Disratthakit, A.; Prammananan, T.; Tribuddharat, C.; Thaipisuttikul, I.; Doi, N.; Leechawengwongs, M.; Chaiprasert, A. Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates. Antimicrob. Agents Chemother. 2016, 60, 5189-5197, 10.1128/AAC.00539-16
88. Watanabe, S.; Matsumura, K.; Iwai, H.; Funatogawa, K.; Haishima, Y.; Fukui, C.; Okumura, K.; Kato-Miyazawa, M.; Hashimoto, M.; Teramoto, K.; Kirikae, F.; Miyoshi-Akiyama, T.; Kirikae, T. A mutation in the 16S rRNA decoding region attenuates the virulence of Mycobacterium tuberculosis. Infect. Immun. 2016, 84, 2264-2273, 10.1128/IAI.00417-16
89. Tahlan, K.; Wilson, R.; Kastrinsky, D. B.; Arora, K.; Nair, V.; Fischer, E.; Barnes, S. W.; Walker, J. R.; Alland, D.; Barry, C. E.; Boshoff, H. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56, 1797-1809, 10.1128/AAC.05708-11
90. Tang, J.; Wang, B.; Wu, T.; Wan, J.; Tu, Z.; Njire, M.; Wan, B.; Franzblauc, S. G.; Zhang, T.; Lu, X.; Ding, K. Design, synthesis, and biological evaluation of pyrazolo [1, 5-a] pyridine-3-carboxamides as novel antitubercular agents. ACS Med. Chem. Lett. 2015, 6, 814-818, 10.1021/acsmedchemlett.5b00176
91. Evans, J. C.; Trujillo, C.; Wang, Z.; Eoh, H.; Ehrt, S.; Schnappinger, D.; Boshoff, H. I.; Rhee, K. Y.; Barry, C. E., III; Mizrahi, V. Validation of CoaBC as a bactericidal target in the coenzyme A pathway of Mycobacterium tuberculosis. ACS Infect. Dis. 2016, 2, 958-968, 10.1021/acsinfecdis.6b00150
92. Chipman, D.; Barak, Z. e.; Schloss, J. V. Biosynthesis of 2-aceto-2-hydroxy acids: Acetolactate synthases and acetohydroxyacid synthases. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1998, 1385, 401-419, 10.1016/S0167-4838(98)00083-1
93. Chikhale, R. V.; Pant, A. M.; Menghani, S. S.; Khedekar, P. B. Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection. BMC Infect. Dis. 2014, 14, E24, 10.1186/1471-2334-14-S3-E24
94. Léger, M.; Gavalda, S.; Guillet, V.; van der Rest, B.; Slama, N.; Montrozier, H.; Mourey, L.; Quémard, A.; Daffé, M.; Marrakchi, H. The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem. Biol. 2009, 16, 510-519, 10.1016/j.chembiol.2009.03.012
95. Terwilliger, T.; Park, M.; Waldo, G.; Berendzen, J.; Hung, L.-W.; Kim, C.-Y.; Smith, C.; Sacchettini, J.; Bellinzoni, M.; Bossi, R.; De Rossi, E.; Mattevi, A.; Milano, A.; Riccardi, G.; Rizzi, M.; Roberts, M. M.; Coker, A. R.; Fossati, G.; Mascagni, P.; Coates, A. R.; Wood, S. P.; Goulding, C. W.; Apostol, M. I.; Anderson, D. H.; Gill, H. S.; Eisenberg, D. S.; Taneja, B.; Mande, S.; Pohl, E.; Lamzin, V.; Tucker, P.; Wilmanns, M.; Colovos, C.; Meyer-Klaucke, W.; Munro, A. W.; McLean, K. J.; Marshall, K. R.; Leys, D.; Yang, J. K.; Yoon, H. J.; Lee, B. I.; Lee, M. G.; Kwak, J. E.; Han, B. W.; Lee, J. Y.; Baek, S. H.; Suh, S. W.; Komen, M. M.; Arcus, V. L.; Baker, E. N.; Lott, J. S.; Jacobs, W.; Alber, T.; Rupp, B. The TB structural genomics consortium: A resource for Mycobacterium tuberculosis biology. Tuberculosis 2003, 83, 223-249, 10.1016/S1472-9792(03)00051-9
96. Singh, S. India takes an open source approach to drug discovery. Cell 2008, 133, 201-203, 10.1016/j.cell.2008.04.003
97. Global Alliance for TB Drug Development. TB Knows No Boundaries; TB Alliance, 2011.
98. Ginsberg, A. Research Spotlight: The TB Alliance: Overcoming challenges to chart the future course of TB drug development. Future Med. Chem. 2011, 3, 1247-1252, 10.4155/fmc.11.82
99. Cole, S. T.; Riccardi, G. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 2011, 14, 570-576, 10.1016/j.mib.2011.07.022
100. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discovery 2007, 6, 29-40, 10.1038/nrd2201
101. Cole, S.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.; Eiglmeier, K.; Gas, S.; Barry, C.; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393, 537, 10.1038/31159
102. Brecik, M.; Centárová, I.; Mukherjee, R.; Kolly, G. l. S.; Huszár, S.; Bobovská, A.; Kilacsková, E. k.; Mokošová, V.; Svetlíková, Z.; Šarkan, M.; Neres, J.; Kordulakova, J.; Cole, S. T.; Mikusova, K. DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem. Biol. 2015, 10, 1631-1636, 10.1021/acschembio.5b00237
103. Riccardi, G.; Pasca, M. R.; Chiarelli, L. R.; Manina, G.; Mattevi, A.; Binda, C. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Appl. Microbiol. Biotechnol. 2013, 97, 8841-8848, 10.1007/s00253-013-5218-x
104. Rombouts, Y.; Brust, B.; Ojha, A. K.; Maes, E.; Coddeville, B.; Elass-Rochard, E.; Kremer, L.; Guerardel, Y. Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to mycolyl-arabinogalactan-peptidoglycan metabolism. J. Biol. Chem. 2012, 287, 11060-11069, 10.1074/jbc.M111.327387
105. Rozwarski, D. A.; Grant, G. A.; Barton, D. H.; Jacobs, W. R.; Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279, 98-102, 10.1126/science.279.5347.98
106. Mikušová, K.; Huang, H.; Yagi, T.; Holsters, M.; Vereecke, D.; D'Haeze, W.; Scherman, M. S.; Brennan, P. J.; McNeil, M. R.; Crick, D. C. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol. 2005, 187, 8020-8025, 10.1128/JB.187.23.8020-8025.2005
107. Silhavy, T. J.; Kahne, D.; Walker, S. The bacterial cell envelope. Cold Spring Harbor Perspect. Biol. 2010, 2, a000414, 10.1101/cshperspect.a000414
108. Wolucka, B. A. Biosynthesis of D-arabinose in mycobacteria-a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 2008, 275, 2691-2711, 10.1111/j.1742-4658.2008.06395.x
109. Chikhale, R.; Menghani, S.; Babu, R.; Bansode, R.; Bhargavi, G.; Karodia, N.; Rajasekharan, M.; Paradkar, A.; Khedekar, P. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. Eur. J. Med. Chem. 2015, 96, 30-46, 10.1016/j.ejmech.2015.04.011
110. Neres, J.; Pojer, F.; Molteni, E.; Chiarelli, L. R.; Dhar, N.; Boy-Röttger, S.; Buroni, S.; Fullam, E.; Degiacomi, G.; Lucarelli, A. P.; Read, R. J.; Zanoni, G.; Edmondson, D. E.; De Rossi, E.; Pasca, M. R.; McKinney, J. D.; Dyson, P. J.; Riccardi, G.; Mattevi, A.; Cole, S. T.; Binda, C. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 2012, 4, 150ra121, 10.1126/scitranslmed.3004395
111. Batt, S. M.; Jabeen, T.; Bhowruth, V.; Quill, L.; Lund, P. A.; Eggeling, L.; Alderwick, L. J.; Fütterer, K.; Besra, G. S. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 11354-11359, 10.1073/pnas.1205735109
112. Landge, S.; Ramachandran, V.; Kumar, A.; Neres, J.; Murugan, K.; Sadler, C.; Fellows, M. D.; Humnabadkar, V.; Vachaspati, P.; Raichurkar, A.; Sharma, S.; Ravishankar, S.; Guptha, S.; Sambandamurthy, V. K.; Balganesh, T. S.; Ugarkar, B. G.; Balasubramanian, V.; Bandodkar, B. S.; Panda, M. Nitroarenes as antitubercular agents: Stereoelectronic modulation to mitigate mutagenicity. ChemMedChem 2016, 11, 331-339, 10.1002/cmdc.201500462
113. Landge, S.; Mullick, A. B.; Nagalapur, K.; Neres, J.; Subbulakshmi, V.; Murugan, K.; Ghosh, A.; Sadler, C.; Fellows, M. D.; Humnabadkar, V.; Mahadevaswamy, J.; Vachaspati, P.; Sharma, S.; Kaur, P.; Mallya, M.; Rudrapatna, S.; Awasthy, D.; Sambandamurthy, V. K.; Pojer, F.; Cole, S. T.; Balganesh, T. S.; Ugarkar, B. G.; Balasubramanian, V.; Bandodkar, B. S.; Panda, M.; Ramachandran, V. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose 2′-oxidase. Bioorg. Med. Chem. 2015, 23, 7694-7710, 10.1016/j.bmc.2015.11.017
114. Neres, J.; Hartkoorn, R. C.; Chiarelli, L. R.; Gadupudi, R.; Pasca, M. R.; Mori, G.; Venturelli, A.; Savina, S.; Makarov, V.; Kolly, G. S.; Molteni, E.; Binda, C.; Dhar, N.; Ferrari, S.; Brodin, P.; Delorme, V.; Landry, V.; de Jesus Lopes Ribeiro, A. L.; Farina, D.; Saxena, P.; Pojer, F.; Carta, A.; Luciani, R.; Porta, A.; Zanoni, G.; De Rossi, E.; Costi, M. P.; Riccardi, G.; Cole, S. T. 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem. Biol. 2015, 10, 705-714, 10.1021/cb5007163
115. Trefzer, C.; Škovierová, H.; Buroni, S.; Bobovská, A.; Nenci, S.; Molteni, E.; Pojer, F.; Pasca, M. R.; Makarov, V.; Cole, S. T.; Riccardi, G.; Mikusova, K.; Johnsson, K. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1. J. Am. Chem. Soc. 2012, 134, 912-915, 10.1021/ja211042r
116. Makarov, V.; Lechartier, B.; Zhang, M.; Neres, J.; Van der Sar, A. M.; Raadsen, S. A.; Hartkoorn, R. C.; Ryabova, O. B.; Vocat, A.; Decosterd, L. A.; Widmer, N.; Buclin, T.; Bitter, W.; Andries, K.; Pojer, F.; Dyson, P. J.; Cole, S. T. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 2014, 6, 372-383, 10.1002/emmm.201303575
117. Wang, F.; Sambandan, D.; Halder, R.; Wang, J.; Batt, S. M.; Weinrick, B.; Ahmad, I.; Yang, P.; Zhang, Y.; Kim, J.; Hassani, M.; Huszar, S.; Trefzer, C.; Ma, Z.; Kaneko, T.; Mdluli, K. E.; Franzblau, S.; Chatterjee, A. K.; Johnsson, K.; Mikusova, K.; Besra, G. S.; Fütterer, K.; Robbins, S. H.; Barnes, S. W.; Walker, J. R.; Jacobs, W. R.; Schultz, P. G. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E2510-E2517, 10.1073/pnas.1309171110
118. Li, H.; Jogl, G. Crystal structure of decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium smegmatis. Proteins: Struct., Funct., Genet. 2013, 81, 538-543, 10.1002/prot.24220
119. Tiwari, R.; Moraski, G. C.; Krchňák, V.; Miller, P. A.; Colon-Martinez, M.; Herrero, E.; Oliver, A. G.; Miller, M. J. Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents. J. Am. Chem. Soc. 2013, 135, 3539-3549, 10.1021/ja311058q
120. Nguyen, L.; Thompson, C. J. Foundations of antibiotic resistance in bacterial physiology: The mycobacterial paradigm. Trends Microbiol. 2006, 14, 304-312, 10.1016/j.tim.2006.05.005
121. Guidelines for the Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update; World Health Organization, 2017.
122. Palomino, J. C.; Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 2014, 3, 317-340, 10.3390/antibiotics3030317
123. Karakousis, P. C. Mechanisms of action and resistance of antimycobacterial agents. In Antimicrobial Drug Resistance; Springer, 2009; pp 271-291, 10.1007/978-1-59745-180-2-24.
124. Damtie, D.; Woldeyohannes, D.; Mathewos, B. Review on molecular mechanism of first line antibiotic resistance in Mycobacterium tuberculosis. Mycobact. Dis. 2014, 4, 1000174, 10.4172/2161-1068.1000174
125. Bakonyte, D.; Baranauskaite, A.; Cicenaite, J.; Sosnovskaja, A.; Stakenas, P. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob. Agents Chemother. 2003, 47, 2009-2011, 10.1128/AAC.47.6.2009-2011.2003
126. Wade, M. M.; Zhang, Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front. Biosci., Landmark Ed. 2004, 9, 975-994, 10.2741/1289
127. Ocheretina, O.; Escuyer, V. E.; Mabou, M.-M.; Royal-Mardi, G.; Collins, S.; Vilbrun, S. C.; Pape, J. W.; Fitzgerald, D. W. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: Investigation of cases with discrepant susceptibility results. PLoS One 2014, 9, e90569, 10.1371/journal.pone.0090569
128. Thirumurugan, R.; Kathirvel, M.; Vallayyachari, K.; Surendar, K.; Samrot, A. V.; Muthaiah, M. Molecular analysis of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis isolates by multiple allele specific polymerase chain reaction in Puducherry, South India. J. Infect. Public Health 2015, 8, 619-625, 10.1016/j.jiph.2015.05.003
129. Njire, M.; Tan, Y.; Mugweru, J.; Wang, C.; Guo, J.; Yew, W.; Tan, S.; Zhang, T. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv. Med. Sci. 2016, 61, 63-71, 10.1016/j.advms.2015.09.007
130. Gu, Y.; Yu, X.; Jiang, G.; Wang, X.; Ma, Y.; Li, Y.; Huang, H. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn. Microbiol. Infect. Dis. 2016, 84, 207-211, 10.1016/j.diagmicrobio.2015.10.017
131. Scorpio, A.; Lindholm-Levy, P.; Heifets, L.; Gilman, R.; Siddiqi, S.; Cynamon, M.; Zhang, Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1997, 41, 540-543
132. Jureén, P.; Werngren, J.; Toro, J.-C.; Hoffner, S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2008, 52, 1852-1854, 10.1128/AAC.00110-08
133. Telenti, A.; Philipp, W. J.; Sreevatsan, S.; Bernasconi, C.; Stockbauer, K. E.; Wieles, B.; Musser, J. M.; Jacobs, W. R., Jr The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 1997, 3, 567-570, 10.1038/nm0597-567
134. Islam, M. M.; Hameed, H. A.; Mugweru, J.; Chhotaray, C.; Wang, C.; Tan, Y.; Liu, J.; Li, X.; Tan, S.; Ojima, I.; Yew, W. W.; Nuermberger, E.; Lamichhane, G.; Zhang, T. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J. Genet. Genomics 2017, 44, 21-37, 10.1016/j.jgg.2016.10.002
135. Ramaswamy, S. V.; Amin, A. G.; Göksel, S.; Stager, C. E.; Dou, S.-J.; El Sahly, H.; Moghazeh, S. L.; Kreiswirth, B. N.; Musser, J. M. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2000, 44, 326-336, 10.1128/AAC.44.2.326-336.2000
136. Safi, H.; Lingaraju, S.; Amin, A.; Kim, S.; Jones, M.; Holmes, M.; McNeil, M.; Peterson, S. N.; Chatterjee, D.; Fleischmann, R.; Alland, D. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat. Genet. 2013, 45, 1190-1197, 10.1038/ng.2743
137. Shi, D.; Li, L.; Zhao, Y.; Jia, Q.; Li, H.; Coulter, C.; Jin, Q.; Zhu, G. Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J. Antimicrob. Chemother. 2011, 66, 2240-2247, 10.1093/jac/dkr284
138. de Jesus Lopes Ribeiro, A. L.; Degiacomi, G.; Ewann, F.; Buroni, S.; Incandela, M. L.; Chiarelli, L. R.; Mori, G.; Kim, J.; Contreras-Dominguez, M.; Park, Y. S.; Han, S. J.; Brodin, P.; Valentini, G.; Rizzi, M.; Riccardi, G.; Pasca, M. R. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. PLoS One 2011, 6, e26675, 10.1371/journal.pone.0026675
139. Foo, C. S.-Y.; Lechartier, B.; Kolly, G. S.; Boy-Röttger, S.; Neres, J.; Rybniker, J.; Lupien, A.; Sala, C.; Piton, J.; Cole, S. T. Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2016, 60, 6451-6459, 10.1128/AAC.01523-16
140. Alekshun, M. N.; Levy, S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007, 128, 1037-1050, 10.1016/j.cell.2007.03.004
141. Warrier, T.; Martinez-Hoyos, M.; Marin-Amieva, M.; Colmenarejo, G.; Porras-De Francisco, E.; Alvarez-Pedraglio, A. I.; Fraile-Gabaldon, M. T.; Torres-Gomez, P. A.; Lopez-Quezada, L.; Gold, B.; Roberts, J.; Ling, Y.; Somersan-Karakaya, S.; Little, D.; Cammack, N.; Nathan, C.; Mendoza-Losana, A. Identification of novel anti-mycobacterial compounds by screening a pharmaceutical small-molecule library against nonreplicating Mycobacterium tuberculosis. ACS Infect. Dis. 2015, 1, 580-585, 10.1021/acsinfecdis.5b00025
142. Warrier, T.; Kapilashrami, K.; Argyrou, A.; Ioerger, T. R.; Little, D.; Murphy, K. C.; Nandakumar, M.; Park, S.; Gold, B.; Mi, J.; Zhang, T.; Meiler, E.; Rees, M.; Somersan-Karakaya, S.; Porras-De Francisco, E.; Martinez-Hoyos, M.; Burns-Huang, K.; Roberts, J.; Ling, Y.; Rhee, K. Y.; Mendoza-Losana, A.; Luo, M.; Nathan, C. F. N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2016, 113, E4523-E4530, 10.1073/pnas.1606590113
143. Makarov, A. V.; Cole, S. T.; Möllmann, U. New Benzothiazinone Derivatives and Their Use as Antibacterial Agents. EP Patent EP2029583 B1, July 09, 2010.
144. Gao, C.; Ye, T.-H.; Wang, N.-Y.; Zeng, X.-X.; Zhang, L.-D.; Xiong, Y.; You, X.-Y.; Xia, Y.; Xu, Y.; Peng, C. T.; Zuo, W. Q.; Wei, Y.; Yu, L. T. Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorg. Med. Chem. Lett. 2013, 23, 4919-4922, 10.1016/j.bmcl.2013.06.069
145. Peng, C.-T.; Gao, C.; Wang, N.-Y.; You, X.-Y.; Zhang, L.-D.; Zhu, Y.-X.; Xv, Y.; Zuo, W.-Q.; Ran, K.; Deng, H. X.; Lei, Q.; Xiao, K. J.; Yu, L. T. Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1, 3-benzothiazin-4-one derivatives. Bioorg. Med. Chem. Lett. 2015, 25, 1373-1376, 10.1016/j.bmcl.2015.02.061
146. Tiwari, R.; Miller, P. A.; Cho, S.; Franzblau, S. G.; Miller, M. J. Syntheses and antituberculosis activity of 1, 3-benzothiazinone sulfoxide and sulfone derived from BTZ043. ACS Med. Chem. Lett. 2015, 6, 128-133, 10.1021/ml5003458
147. Trefzer, C.; Rengifo-Gonzalez, M.; Hinner, M. J.; Schneider, P.; Makarov, V.; Cole, S. T.; Johnsson, K. Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 2010, 132, 13663-13665, 10.1021/ja106357w
148. Kloss, F.; Krchnak, V.; Krchnakova, A.; Schieferdecker, S.; Dreisbach, J.; Krone, V.; Möllmann, U.; Hoelscher, M.; Miller, M. J. In ivo dearomatization of the potent antituberculosis agent BTZ043 via meisenheimer complex formation. Angew. Chem., Int. Ed. 2017, 56, 2187-2191, 10.1002/anie.201609737
149. Mir, F.; Shafi, S.; Zaman, M.; Kalia, N. P.; Rajput, V. S.; Mulakayala, C.; Mulakayala, N.; Khan, I. A.; Alam, M. Sulfur rich 2-mercaptobenzothiazole and 1, 2, 3-triazole conjugates as novel antitubercular agents. Eur. J. Med. Chem. 2014, 76, 274-283, 10.1016/j.ejmech.2014.02.017
150. Magnet, S.; Hartkoorn, R. C.; Székely, R.; Pató, J.; Triccas, J. A.; Schneider, P.; Szántai-Kis, C.; OÌrfi, L.; Chambon, M.; Banfi, D.; Bueno, M.; Turcatti, G.; Keri, G.; Cole, S. T. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 2010, 90, 354-360, 10.1016/j.tube.2010.09.001
151. No, Z.; Kim, J.; Brodin, P.; Seo, M. J.; Kim, Y. M.; Cechetto, J.; Jeon, H.; Genovesio, A.; Lee, S.; Kang, S.; Ewann, F. N.; Nam, J. Y.; Christophe, T.; Fenistein, D. P.; Jamung, H.; Jiyeon, J. Anti-Infective Compounds. World Patent WO2011113606 A1, Sep 22, 2011.
152. Makarov, V.; Neres, J.; Hartkoorn, R. C.; Ryabova, O. B.; Kazakova, E.; Šarkan, M.; Huszár, S.; Piton, J.; Kolly, G. S.; Vocat, A.; Conroy, T. M.; Mikusova, K.; Cole, S. T. The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2015, 59, 4446-4452, 10.1128/AAC.00778-15
153. Liu, R.; Lyu, X.; Batt, S. M.; Hsu, M. H.; Harbut, M. B.; Vilchèze, C.; Cheng, B.; Ajayi, K.; Yang, B.; Yang, Y.; Guo, H.; Lin, C.; Gan, F.; Wang, C.; Franzblau, S. G.; Jacobs, W. R.; Besra, G. S.; Johnson, E. F.; Petrassi, M.; Chatterjee, A. K.; Fütterer, K.; Wang, F. Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes. Angew. Chem., Int. Ed. 2017, 56, 13011-13015, 10.1002/anie.201707324
154. Batt, S. M.; Cacho Izquierdo, M.; Castro Pichel, J.; Stubbs, C. J.; Vela-Glez Del Peral, L.; Pérez-Herrán, E.; Dhar, N.; Mouzon, B.; Rees, M.; Hutchinson, J. P.; Young, R. J.; McKinney, J. D.; Barros Aguirre, D.; Ballell, L.; Besra, G. S.; Argyrou, A. Whole cell target engagement identifies novel inhibitors of Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase. ACS Infect. Dis. 2015, 1, 615-626, 10.1021/acsinfecdis.5b00065
155. Brodin, P.; Christophe, T.; No, Z.; Kim, J.; Genovesio, A.; Fenistein, D. P. C.; Jeon, H.; Ewann, F. A.; Kang, S.; Lee, S. Anti-Infective Compounds. World Patent WO2010003533 A2, Nov 11, 2010.
156. No, Z.; Kim, J.; Brodin, P.; Seo, M. J.; Eunjung, P.; Cechetto, J.; Jeon, H.; Kim, E.; Heo, J.; Nam, J. Y. Anti-Infective Pyrido(1,2-a)pyrimidines. World Patent WO2011085990 A1, July, 21, 2011.
157. Shirude, P. S.; Shandil, R.; Sadler, C.; Naik, M.; Hosagrahara, V.; Hameed, S.; Shinde, V.; Bathula, C.; Humnabadkar, V.; Kumar, N.; Reddy, J.; Panduga, V.; Sharma, S.; Ambady, A.; Hegde, N.; Whiteaker, J.; McLaughlin, R. E.; Gardner, H.; Madhavapeddi, P.; Ramachandran, V.; Kaur, P.; Narayan, A.; Guptha, S.; Awasthy, D.; Narayan, C.; Mahadevaswamy, J.; Vishwas, K. G.; Ahuja, V.; Srivastava, A.; Prabhakar, K. R.; Bharath, S.; Kale, R.; Ramaiah, M.; Choudhury, N. R.; Sambandamurthy, V. K.; Solapure, S.; Iyer, P. S.; Narayanan, S.; Chatterji, M. Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J. Med. Chem. 2013, 56, 9701-9708, 10.1021/jm401382v
158. Chatterji, M.; Shandil, R.; Manjunatha, M.; Solapure, S.; Ramachandran, V.; Kumar, N.; Saralaya, R.; Panduga, V.; Reddy, J.; Prabhakar, K.; Sharma, S.; Sadler, C.; Cooper, C. B.; Mdluli, K.; Iyer, P. S.; Narayanan, S.; Shirude, P. S. 1,4-Azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrob. Agents Chemother. 2014, 58, 5325-5331, 10.1128/AAC.03233-14
159. Shirude, P. S.; Shandil, R. K.; Manjunatha, M.; Sadler, C.; Panda, M.; Panduga, V.; Reddy, J.; Saralaya, R.; Nanduri, R.; Ambady, A.; Ravishankar, S.; Sambandamurthy, V. K.; Humnabadkar, V.; Jena, L. K.; Suresh, R. S.; Srivastava, A.; Prabhakar, K. R.; Whiteaker, J.; McLaughlin, R. E.; Sharma, S.; Cooper, C. B.; Mdluli, K.; Butler, S.; Iyer, P. S.; Narayanan, S.; Chatterji, M. Lead optimization of 1, 4-azaindoles as antimycobacterial agents. J. Med. Chem. 2014, 57, 5728-5737, 10.1021/jm500571f
160. https://www.tballiance.org/portfolio/compound/tba-7371-dpre1-inhibitor' (accessed May 15, 2018).
161. Panda, M.; Ramachandran, S.; Ramachandran, V.; Shirude, P. S.; Humnabadkar, V.; Nagalapur, K.; Sharma, S.; Kaur, P.; Guptha, S.; Narayan, A.; Mahadevaswamy, J.; Ambady, A.; Hegde, N.; Rudrapatna, S. S.; Hosagrahara, V. P.; Sambandamurthy, V. K.; Raichurkar, A. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J. Med. Chem. 2014, 57, 4761-4771, 10.1021/jm5002937
162. Naik, M.; Humnabadkar, V.; Tantry, S. J.; Panda, M.; Narayan, A.; Guptha, S.; Panduga, V.; Manjrekar, P.; Jena, L. K.; Koushik, K.; Shanbhag, G.; Jatheendranath, S.; Manjunatha, M. R.; Gorai, G.; Bathula, C.; Rudrapatna, S.; Achar, V.; Sharma, S.; Ambady, A.; Hegde, N.; Mahadevaswamy, J.; Kaur, P.; Sambandamurthy, V. K.; Awasthy, D.; Narayan, C.; Ravishankar, S.; Madhavapeddi, P.; Reddy, J.; Prabhakar, K.; Saralaya, R.; Chatterji, M.; Whiteaker, J.; McLaughlin, B.; Chiarelli, L. R.; Riccardi, G.; Pasca, M. R.; Binda, C.; Neres, J.; Dhar, N.; Signorino-Gelo, F.; McKinney, J. D.; Ramachandran, V.; Shandil, R.; Tommasi, R.; Iyer, P. S.; Narayanan, S.; Hosagrahara, V.; Kavanagh, S.; Dinesh, N.; Ghorpade, S. R. 4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. J. Med. Chem. 2014, 57, 5419-5434, 10.1021/jm5005978